Anti-inflammatory and Anti-cancer Properties of β-Escin, a Triterpene Saponin

Current Pharmacology Reports

Volumn 1, Issue 3, 2015, Pages 170-178

  Patlolla, Jagan M R ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Bioavailability; Cancer prevention; Horse chestnut seed extract; Pharmacokinetics; Escin

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; ALDEHYDE DEHYDROGENASE; BETA ESCIN; CYCLIN D1; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P21; REACTIVE OXYGEN METABOLITE; SAPONIN DERIVATIVE; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRITERPENE APONIN; UNCLASSIFIED DRUG;

AESCULUS HIPPOCASTANUM; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CELL PROLIFERATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; ENZYME ACTIVITY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VEIN INSUFFICIENCY;

EID: 85010386604     PISSN: None     EISSN: 2198641X     Source Type: Journal    
DOI: 10.1007/s40495-015-0019-9     Document Type: Review

References (65)

1. World Health Organization. Health Report, 2006. Lyon: WHO Publications Press; 2006.
2. Chronic Disease Prevention. Center for Disease Control, Annual Report (2006).
3. Patlolla JM, Rao CV. Triterpenoids for cancer prevention and treatment: current status and future prospects. Curr Pharm Biotechnol. 2012;13(1):147–55.
4. Rao AV, Gurfinkel DM. The bioactivity of saponins: triterpenoid and steroidal glycosides. Drug Metabol Drug Interact. 2000;17(1–4):211–35. This review summarizes the saponins chemistry, metabolism and in role in different diseases.
5. Challinor VL, De Voss JJ. Open-chain steroidal glycosides, a diverse class of plant saponins. Nat Prod Rep. 2013;30(3):429–54.
6. Bruneton J. Pharmacognosy, Phytochemistry, Medicinal Plants. Lavoisier Publishing, Paris, 1995; pp. 538–544 (ISBN 2-4730-0028-7).
7. Project Summary: Functional Genomics of Triterpene Saponin Biosynthesis in Medicago Truncatula. “http://www.noble.org/Plantbio/Dixon/Personnel/projectsummaries/Saponin.html
8. Sparg SG, Light ME, van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol. 2004;94:219–43.
9. De Geyter E, Lambert E, Geelen D, Smagghe G. Novel advances with plant saponins as natural insecticides to control pest insects. Pest Tech. 2007;2:96–105.
10. Vincken JP, Heng L, de Groot A, Gruppen H. Saponins, classification and occurrence in the plant kingdom. Phytochemistry. 2007;68(3):275–97.
11. Hardin JW. A revision of the American Hippocastanaceae. Brittonia. 1957;9:145–71.
12. Raven PH, Axelrod KI. Angiosperm biogeography and past continental movements. Ann Mo Bot Gard. 1974;61:539–673.
13. Xiang Q-Y, Crawford DJ, Wolfe AD, Tang Y-C, DePamphilis CW. Origin and biogeography of Aesculus L. (Hippocastanaceae): a molecular phylogenetic perspective. Evolution. 1998;52(4):988–97.
14. Griffini A, Lolla E, Petrlongo F. Liquid chromatography-thermospray mass spectrometry analysis of β-escin. Fitoterapia. 1997;68:520–6.
15. Wei F, Mal LY, Cheng XL, Lin RCH. Preparative HPLC for purification of four isomeric bioactive saponins from the seeds of Aesculus chinensis. J Liq Chromatogr Relat Technol. 2005;28:763–73. In this paper a detailed methodology for isolation and purification of isomeric escins from crude extracts of aesculus plants have been reported.
16. Guo W, Xu B, Yang XW, Liu Q, Cui JR. The anticancer effect of β-escin sodium. Chin Pharmacol Bull. 2003;19:351–2.
17. Patlolla JM, Raju J, Swamy MV, Rao CV. Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21 (waf1/cip1) in colon cancer cells. Mol Cancer Ther. 2006;5(6):1459–66. This paper for the first time demonstrates the functional characterization of β-Escin’s anti-proliferation characteristics which decreased the phosphorylation of retinoblastoma protein in colon cancer cells and in an experimental colon cancer pre-clinical animal model.
18. Zhou XY, Fu FH, Li Z, Dong QJ, He J, Wang CH. Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. Planta Med. 2009;75:1580–5.
19. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol. 2010;77(5):818–27.
20. Piao S, Kang M, Lee YJ, Choi WS, Chun YS, Kwak C, Kim HH. Cytotoxic Effects of Escin on Human Castration-resistant Prostate Cancer Cells Through the Induction of Apoptosis and G2/M Cell Cycle Arrest. Urology, 2014; pjj: S0090-4295(14) 00631–1.
21. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G. Identification of β-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2010;334(1):285–93.
22. Ming ZJ, Hu Y, Qiu YH, Cao L, Zhang XG. Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine. 2010;17(8):575–80.
23. Shen DY, Kang JH, Song W, Zhang WQ, Li WG, Zhao Y, et al. Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspase-dependent pathway. Phytother Res. 2011;25(10):1519–26.
24. Ji DB, Xu B, Liu JT, Ran FX, Cui JR. β-escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog. 2011;50(12):945–60.
25. Wang YW, Wang SJ, Zhou YN, Pan SH, Sun B. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-kB and nuclear factor-kB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 2012;138(5):785–97. In this paper β-Escin in combination with gemcitabine increases anti-tumor activity and chemotherapeutic activity of gemcitabine against Pancreatic cancer which is an aggressive malignancy in present day condition.
26. Patlolla JM, Qian L, Biddick L, Zhang Y, Desai D, Amin S, et al. β-Escin inhibits NNK-induced lung adenocarcinoma and ALDH1A1 and RhoA/ROCK expression in A/J mice and growth of H460 human lung cancer cells. Cancer Prev Res. 2013;6(10):1140–9. This paper demonstrates for the first time the efficacy of β-Escin in chemoprevention of lung cancer using A/J mouse lung tumour bioassay and also against stem cell marker.
27. Sirtori A. Pharmacology, pharmacokinetics and therapeutics profile. Pharmacol Res. 2001;44(3):183–93.
28. Yoshikawa M, Murakami T, Matsuda H, Yamahara J, Murakami N, Kitagawa I. Bioactive saponins and glycosides. III. Horse chestnut (1): the Structures, inhibitory effects on ethanol absorption, and hypoglycemic activity of escins Ia, Ib, IIa, IIb, and IIIa from the seeds of Aesculus hippocastanum L. Chem Pharm Bull. 1996;44(8):1454–64.
29. Yoshikawa M, Murakami T, Yamahara J, Matsuda H. Bioactive saponins and glycosides. XII. Horse chestnut. (2): structures of escins IIIb, IV, V, and VI and isoescins Ia, Ib, and V, acylated polyhydroxyoleanene triterpene oligoglycosides, from the seeds of horse chestnut tree (Aesculus hippocastanum L., Hippocastanaceae). Chem Pharm Bull. 1998;46(11):1764–9.
30. Haralampidis K, Trojanowska M, Osbourn AE. Biosynthesis of triterpenoid saponins in plants. Adv Biochem Eng Biotechnol. 2002;75:31–49.
31. Matsuda H, Li Y, Muakami T, Ningmiya K, Yamahara I, Yoshikawa M. Effects of escins Ia, Ib, IIa, Iib from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull. 1997;20(10):1092–5.
32. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoXavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005;65(15):6934–42.
33. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic signiWcance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6(5):1796–803.
34. Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005;65(6):2344–52.
35. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006;66(21):10553–9.
36. Rimmon A, Vexler A, Berkovich L, Earon G, Ron I, Lev-Ari S. Escin chemosensitizes human pancreatic cancer cells and inhibits the nuclear factor-kappaB signaling pathway. Biochem Res Int. 2013. doi:10.1155/2013/251752.
37. Guney G, Kutlu HM, Iscan A. The apoptotic effects of escin in the H-Ras transformed 5RP7 cell line. Phytother Res. 2012;27(6):900--5.
38. Lee HS, Hong JE, Kim EJ, Kim SH. Escin suppresses migration and invasion involving the alteration of CXCL16/CXCR6 axis in human gastric adenocarcinoma AGS cells. Nutr Cancer. 2014;66(6):938–45.
39. Yang XW, Zhao J, Cui JR, Guo W. Studies on the biotransformation of escin Ia by human intestinal bacteria and the anti-tumor activities of desacylescin 1. Beijing Da Xue Bao. 2004;36(1):31–5.
40. Wu XJ, Zhang ML, Cui XY, Gao F, He Q, Li XJ, et al. Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat. J Ethnopharmacol. 2012;139(1):201–6. This paper summarizes the pharmacokinetic and bioavailability of different isomers of escin extracted from horsechestnut seed and from that of pure escin.
41. Ma CF, Li L. Clinical observation of the curative effects of a combination of sodium aescinate and glycerol fructose on joint swelling after calcaneal fracture. Chin Pharm. 2008;11:445–6.
42. Tang L. Clinical observation of the curative effects of sodium aescinate on swelling after ankle fracture. Mod Med J. 2008;36:105–6.
43. Yang LD, Liu F. Clinical observation of the curative effects of sodium aescinate on limb swelling resulting from fracture of tibia and fibula. Acta Acad Med Nantong. 2009;29:34–5.
44. Pabst H, Segesser B, Bulitta M, Wetzel D, Bertram S. Efficacy and tolerability of escin/diethylamine salicylate combination gels in patients with blunt injuries of the extremities. Int J Sports Med. 2001;22(6):430–6.
45. Montenegro L, Carbone C, Giannone I, Puglisi G. Use of solid phase extraction(SPE) to evaluate in vitro skin permeation of aescin. Pharmazie. 2007;62(5):342–5.
46. Schrader E, Schwankl W, Sieder C, Christoffel V. Comparison of the bioavailability of beta-aescin after single oral administration of two different drug formulations containing an extract of horse-chestnut seeds. Pharmazie. 1995;50:623–7.
47. Loew D, Schrodter A, Schwankl W, Marz RW. Measurement of the bioavailability of aescin-containing extracts. Methods Find Exp Clin Pharmacol. 2000;22:537–42.
48. Liu L, Wu X, Wu D, Wang Y, Li P, Sun Y, et al. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of escin Ia and escin IB in human plasma: application to a pharmacokinetic study after intravenous administration. Biomed Chromatogr. 2010;24(12):1309–15.
49. Wu X, Liu L, Zhang M, Wu D, Wang Y, Sun Y, et al. Simultaneous analysis of isomers of escin saponins in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(11–12):861–7.
50. Oschmann R, Biber A, Lang F, Stumf H, Kunz K. Pharmacokinetics of beta-escin after administration of various Aesculus extract containing formulations. Pharmazie. 1996;51(8):577–81.
51. Greeske K, Pohlmann BK. Horse chestnut seed extract an effective therapy principle in general practice. Drug therapy of chronic venous insufficiency. Fortschr Med. 1996;114(15):196–200.
52. Ottillinger B, Greeske K. Rational therapy of chronic venous insufficiency chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovasc Disord. 2001;1:5.
53. Ernst E, Pittler MH, Stevinson C. Complementary/alternative medicine in dermatology: evidence-assessed efficacy of two diseases and two treatments. Am J Clin Dermatol. 2002;3(5):341–8.
54. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2006;25(1):CD 003230.
55. Guillaume M, Padioleau F. Veinotonic effect, vascular protection anti-inflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung. 1994;44(1):25–35.
56. Kimura H, Ogawa S, Jisaka M, Kimura Y, Katsube T, Yokota K. Identification of novel saponins from edible seeds of Japanese horse chestnut (Aesculus turbinata Blume) after treatment with wooden ashes and their nutraceutical activity. J Pharm Biomed Anal. 2006;41(5):1657–65.
57. Hu JN, Zhu XM, Han LK, Saito M, Sun YS, Yoshikawa M, et al. Antiobesity effects of escins extracted from the seeds of Aesculus turbinata BLUME (Hippocastanaceae). Chem Pharm Bull (Tokyo). 2008;56(1):12–6.
58. Wetzel D, Menke W, Dieter R, Smasal V, Giannetti B, Bulitta M. Escin/diethylammonium salicylate heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med. 2002;36(3):183–8.
59. Grases F, Garcia-Gonzalez R, Redondo E, Costa-Bauza A, Simonet BM, Sartini RP, et al. Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial. Clin Ther. 2004;26:2045–55.
60. Arnould T, Janssens D, Michiels C, Remacle J. Effect of aescine on hypoxia-induced activation of human endothelial cells. Eur J Pharmacol. 1996;315(2):227–33.
61. Liu S, Wang H, Qiu C, Zhang J, Zhang T, Zhou W, et al. Escin inhibits lipopolysaccharide-induced inflammation in human periodontal ligament cells. Mol Med Rep. 2012;6(5):1150–4.
62. Xin W, Zhang L, Fan H, Jiang N, Wang T, Fu F. Escin attenuates acute lung injury induced by endotoxin in mice. Eur J Pharm Sci. 2011;42(1–2):73–80.
63. Xin W, Zhang L, Sun F, et al. Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro. Phytomedicine. 2011;18(4):272–7.
64. Xiao GM, Wei J. Effects of β-aescin on the expression of nuclear factor-kappa B and tumor necrosis factor-alpha after traumatic brain injury in rats. J Zhejiang Univ Sci B. 2005;6(1):28–32.
65. Lindner I, Meier C, Url A, Unger H, Grassauer A, Prieschl-Grassauer E, et al. Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation. BMC Immunol. 2010;11:24. doi:10.1186/1471-2172-11-24. In this paper potential benefits of β-escin as anti-allergic agent have been summarized.